Clarifying Facts Amid Tylenol Confusion and Misinformation

In a controversial press conference that has sparked widespread debate in the medical community, President Trump and Health and Human Services Secretary Robert F. Kennedy Jr. issued strong warnings against the use of Tylenol (acetaminophen) during pregnancy, linking it to autism and other neurodevelopmental disorders in children.

The unscripted event quickly descended into chaos as Trump veered off message, making the dramatic claim that “we found the cause of autism.” He repeatedly advised pregnant women to “just tough it out” rather than taking Tylenol for pain or fever. The President extended this warning to infants before pivoting to question current childhood vaccination schedules.

Medical experts across the country have expressed alarm at what many characterize as dangerous oversimplification of complex scientific research. Trump’s definitive statements that Tylenol use during pregnancy carries “very high risk” and is “strongly associated with autism” contradict the nuanced findings of extensive research on the subject.

The scientific community has long emphasized that association does not equal causation. Due to ethical constraints, researchers cannot conduct prospective placebo-controlled studies—considered the gold standard for establishing causation—on pregnant women. Instead, all existing studies on Tylenol use during pregnancy are retrospective and observational.

Such observational studies are inherently limited by confounding variables that can create misleading statistical associations. A senior author of a landmark April 2024 Journal of the American Medical Association study on this topic illustrated this concept with a simple analogy: ice cream consumption correlates with drowning deaths not because ice cream causes drowning, but because both increase during hot weather.

Similarly, the conditions that lead pregnant women to take Tylenol—such as fever and infection—have themselves been linked to neurodevelopmental issues when left untreated. These underlying conditions, rather than the medication, could potentially be the causative factors.

The scientific consensus remains far from the certainty suggested at the press conference. A recent comprehensive review in Environmental Health examined 46 studies and found inconsistent results regarding any association between prenatal acetaminophen use and neurodevelopmental outcomes. Critics have noted methodological flaws in some studies that did find associations.

Particularly significant is the JAMA study conducted in Sweden that tracked 2.4 million children over 24 years. While initial results showed an association between Tylenol use and autism, this link disappeared when researchers controlled for siblings who were not exposed to Tylenol during pregnancy—a method that accounts for genetic and environmental factors. Additionally, researchers found no dose-response relationship, which would typically be expected with a true causative agent. A separate Japanese study involving over 200,000 children reached similar conclusions.

Critics argue that federal health officials have selectively cited research to support Kennedy’s agenda while ignoring contradictory evidence. Major medical organizations—including the American Psychiatric Association, the American College of Obstetricians and Gynecologists, the Society for Maternal-Fetal Medicine, and the American Academy of Pediatrics—maintain that judicious use of Tylenol during pregnancy remains safe.

Despite the alarming rhetoric at the press conference and an announcement that safety warnings will be added to Tylenol’s label, the FDA’s actual recommendation remains measured: use the lowest effective dose for the shortest possible duration—standard advice for most medications during pregnancy.

In the aftermath of the controversy, Kennedy has reportedly acknowledged that insufficient evidence exists to support a definitive causative link between Tylenol and autism.

For the approximately four million pregnant women in the United States each year, Tylenol remains one of the few available options for treating pain and fever. Medical professionals continue to advise women to consult with their physicians regarding medication use during pregnancy rather than making decisions based on political statements.

The pharmaceutical industry has yet to issue a formal response to the claims made during the press conference, though Johnson & Johnson, manufacturer of Tylenol, has previously defended the safety profile of acetaminophen when used as directed.